Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

Paloma Cejas; Yotam Drier; Koen M A Dreijerink; Lodewijk A A Brosens; Vikram Deshpande; Charles B Epstein; Elfi B Conemans; Folkert H M Morsink; Mindy K Graham; Gerlof D Valk; Menno R Vriens; Carlos Fernandez-Del Castillo; Cristina R Ferrone; Tomer Adar; Michaela Bowden; Holly J Whitton; Annacarolina Da Silva; Alba Font-Tello; Henry W Long; Elizabeth Gaskell; Noam Shoresh; Christopher M Heaphy; Ewa Sicinska; Matthew H Kulke; Daniel C Chung; Bradley E Bernstein; Ramesh A Shivdasani

doi:10.1038/s41591-019-0573-5

Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

Nat Med. 2019 Oct;25(10):1627. doi: 10.1038/s41591-019-0573-5.

Authors

Paloma Cejas^#^{1

2

3}, Yotam Drier^#^{4

5

6}, Koen M A Dreijerink^{7

8}, Lodewijk A A Brosens⁹, Vikram Deshpande¹⁰, Charles B Epstein¹¹, Elfi B Conemans^{7

8}, Folkert H M Morsink⁹, Mindy K Graham¹², Gerlof D Valk⁷, Menno R Vriens¹³, Carlos Fernandez-Del Castillo¹⁴, Cristina R Ferrone¹⁴, Tomer Adar¹⁵, Michaela Bowden¹, Holly J Whitton¹¹, Annacarolina Da Silva¹⁶, Alba Font-Tello², Henry W Long², Elizabeth Gaskell¹¹, Noam Shoresh¹¹, Christopher M Heaphy¹², Ewa Sicinska¹⁶, Matthew H Kulke^{1

17}, Daniel C Chung¹⁵, Bradley E Bernstein^{18

19}, Ramesh A Shivdasani^{20

21

22}

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
³ Translational Oncology Laboratory, Hospital La Paz Institute for Health Research, Madrid, Spain.
⁴ Broad Institute of Harvard and MIT, Cambridge, MA, USA. [email protected].
⁵ Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. [email protected].
⁶ Lautenberg Center for Immunology and Cancer Research, Hebrew University, Faculty of Medicine, Jerusalem, Israel. [email protected].
⁷ Department of Endocrine Oncology, UMC Utrecht Cancer Center, Utrecht, the Netherlands.
⁸ Department of Internal Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
⁹ Department of Pathology, UMC Utrecht Cancer Center, Utrecht, the Netherlands.
¹⁰ Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
¹¹ Broad Institute of Harvard and MIT, Cambridge, MA, USA.
¹² Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
¹³ Department of Surgical Oncology, UMC Utrecht Cancer Center, Utrecht, the Netherlands.
¹⁴ Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
¹⁵ Department of Gastroenterology Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
¹⁶ Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
¹⁷ Departments of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA.
¹⁸ Broad Institute of Harvard and MIT, Cambridge, MA, USA. [email protected].
¹⁹ Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. [email protected].
²⁰ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected].
²¹ Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected].
²² Departments of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA. [email protected].

^# Contributed equally.

PMID: 31501535
DOI: 10.1038/s41591-019-0573-5

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Publication types

Published Erratum